Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,100 | 65 | 90.1% |
| Education | $121.43 | 8 | 9.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $263.54 | 17 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $185.74 | 12 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $155.38 | 8 | $0 (2024) |
| Amgen Inc. | $125.26 | 6 | $0 (2022) |
| Relypsa, Inc. | $74.01 | 5 | $0 (2020) |
| Genentech USA, Inc. | $71.24 | 5 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $55.63 | 3 | $0 (2019) |
| Shire North American Group Inc | $45.43 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $31.34 | 2 | $0 (2022) |
| CALLIDITAS THERAPEUTICS US INC. | $28.41 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225.13 | 11 | AstraZeneca Pharmaceuticals LP ($55.59) |
| 2023 | $13.22 | 1 | AstraZeneca Pharmaceuticals LP ($13.22) |
| 2022 | $313.49 | 17 | Aurinia Pharma U.S., Inc. ($138.47) |
| 2021 | $90.71 | 5 | AstraZeneca Pharmaceuticals LP ($69.87) |
| 2020 | $76.53 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($17.03) |
| 2019 | $245.34 | 18 | Otsuka America Pharmaceutical, Inc. ($119.11) |
| 2018 | $79.40 | 5 | Amgen Inc. ($21.55) |
| 2017 | $177.47 | 11 | Mallinckrodt LLC ($42.45) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/03/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $25.98 | General |
| Category: NEPHROLOGY | ||||||
| 09/30/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Diabetes | ||||||
| 08/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 07/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: DIABETES | ||||||
| 07/22/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Nephrology | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/01/2024 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/05/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: Genetic Disease | ||||||
| 03/13/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/28/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/25/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: NEPHROLOGY | ||||||
| 08/23/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/29/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Nephrology | ||||||
| 05/11/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Nephrology | ||||||
| 05/10/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 05/03/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: IMMUNOLOGY | ||||||
| 04/08/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $53.32 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 03/24/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Nephrology | ||||||
| 03/11/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.45 | General |
| 03/09/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/03/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 4,732 | 8,615 | $2.3M | $322,445 |
| 2022 | 33 | 4,465 | 7,446 | $1.1M | $315,362 |
| 2021 | 41 | 6,220 | 9,918 | $1.2M | $355,203 |
| 2020 | 39 | 6,700 | 14,205 | $1.4M | $370,787 |
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 38 | 264 | $517,334 | $69,211 | 13.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 160 | 498 | $329,307 | $44,160 | 13.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 272 | 386 | $270,995 | $33,430 | 12.3% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 102 | 497 | $170,898 | $22,742 | 13.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 100 | 495 | $131,274 | $17,630 | 13.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 86 | 425 | $111,231 | $14,908 | 13.4% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 235 | 351 | $86,936 | $14,091 | 16.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 99 | 105 | $101,216 | $13,084 | 12.9% |
| 82306 | Vitamin d-3 level | Office | 2023 | 218 | 311 | $55,234 | $8,971 | 16.2% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 47 | 47 | $67,167 | $8,825 | 13.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 129 | $56,688 | $7,698 | 13.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 49 | 58 | $57,166 | $7,276 | 12.7% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 79 | 79 | $46,608 | $6,013 | 12.9% |
| 82610 | Cystatin c (enzyme inhibitor) level | Office | 2023 | 201 | 287 | $31,891 | $5,193 | 16.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 302 | 493 | $31,236 | $5,075 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 302 | 555 | $9,990 | $4,646 | 46.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 14 | 20 | $32,530 | $4,459 | 13.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 314 | 515 | $24,009 | $3,899 | 16.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 50 | 128 | $27,817 | $3,784 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $27,407 | $3,672 | 13.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 191 | 191 | $19,161 | $3,239 | 16.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 21 | $24,828 | $3,079 | 12.4% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 315 | 532 | $16,317 | $2,996 | 18.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 315 | 528 | $16,410 | $2,669 | 16.3% |
| 84100 | Phosphate level | Office | 2023 | 296 | 478 | $13,594 | $2,210 | 16.3% |
About Dr. Christopher Poole, MD
Dr. Christopher Poole, MD is a Nephrology healthcare provider based in Chattanooga, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558368837.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Poole, MD has received a total of $1,221 in payments from pharmaceutical and medical device companies, with $225.13 received in 2024. These payments were reported across 73 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,100).
As a Medicare-enrolled provider, Poole has provided services to 22,117 Medicare beneficiaries, totaling 40,184 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Chattanooga, TN
- Active Since 07/01/2005
- Last Updated 05/28/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1558368837
Products in Payments
- LUPKYNIS (Drug) $155.38
- LOKELMA (Drug) $137.28
- SAMSCA (Drug) $98.88
- FARXIGA (Drug) $96.27
- JYNARQUE (Drug) $86.86
- Parsabiv (Drug) $85.53
- Veltassa (Drug) $74.01
- Rituxan (Biological) $71.24
- ACTHAR (Biological) $70.24
- Parsabiv (Biological) $39.73
- INJECTAFER (Drug) $31.34
- NATPARA (Drug) $29.67
- TARPEYO (Drug) $28.41
- FABRAZYME (Biological) $27.22
- Vafseo (Drug) $24.61
- Ozempic (Drug) $18.15
- BENLYSTA (Biological) $16.80
- BRILINTA (Drug) $16.54
- GATTEX (Drug) $15.76
- RAYALDEE (Drug) $15.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Chattanooga
Rohit Gupta, M.d, M.D
Nephrology — Payments: $10,529
Hans Yehnert, Md, MD
Nephrology — Payments: $5,326
Nilesh Patel, M.d, M.D
Nephrology — Payments: $3,184
John Mccarley, M.d, M.D
Nephrology — Payments: $2,939
Brant Holt, Md, MD
Nephrology — Payments: $2,929
Mandeep Grewal, Md, MD
Nephrology — Payments: $2,449